TAT |
TAT co-incubation could provoke the uptake of the macropinosytosis marker 70kDa Dextran. |
in vitro |
[73] |
TAT-NPs |
NPs conjugated with TAT could induce bystander uptake of all NP-type cargo but not common fluid markers, the activity of which was regulated by extracellular cysteine presence both in vitro and in vivo.
|
in vitro & in vivo
|
[8] |
Polyarginines |
TAT-fused albumin induced macropinocytosis through interactions with HSPG and CXCR4 to activate PKC/PI3K/JNK/mTOR signaling pathways. |
in vitro |
[72] |
iRGD |
iRGD could facilitate the delivery of small molecule, nanoparticle and antibody into tumors when administered as a combination therapy. |
in vivo |
[59] |
Despite little enhancement of cytotoxicity in vitro, co-administered iRGD promoted the delivery of PLGA nanoparticles selectively into tumors in vivo.
|
in vitro & in vivo
|
[78] |
LyP-1 |
The LyP-1-containing self-microemulsifying formulation not only increased in vitro cytotoxic effect of co-administered doxorubicin hydrochloride, but also achieved preferential accumulation in tumors via intraperitoneal injection. |
in vitro & in vivo
|
[79] |
tLyP-1 |
Following tLyP-1 co-administration, tumor-targeted NPs displayed improved cytotoxicity of the loaded paclitaxel and deeper penetration into the glioma parenchyma. |
in vitro & in vivo
|
[80] |
iNGR |
iNGR enhanced accumulation and efficacy of co-administered doxorubicin by triggering the tumor-specific penetration. |
in vivo |
[82] |